Diagnosis of human fascioliasis: detection of anti-cathepsin L antibodies in blood samples collected on filter paper

Citation
W. Strauss et al., Diagnosis of human fascioliasis: detection of anti-cathepsin L antibodies in blood samples collected on filter paper, AM J TROP M, 60(5), 1999, pp. 746-748
Citations number
9
Categorie Soggetti
Envirnomentale Medicine & Public Health","Medical Research General Topics
Journal title
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
ISSN journal
00029637 → ACNP
Volume
60
Issue
5
Year of publication
1999
Pages
746 - 748
Database
ISI
SICI code
0002-9637(199905)60:5<746:DOHFDO>2.0.ZU;2-L
Abstract
We have developed an ELISA for the diagnosis of human fascioliasis based on the detection of IgG4 antibodies to Fasciola hepatica cathepsin LI cystein e protease. Use of this assay in the Bolivian Altiplano, a region with a hi gh prevalence of the disease, was hampered by the reluctance of the indigen ous population to provide blood. To overcome this problem, we have investig ated the method of collecting small quantities of blood from the finger ont o Biter paper, followed by the elution of antibodies for use in the diagnos tic assay. Serum samples and blood samples collected onto filter paper were obtained from 57 individuals living in the village of Cutusuma in 1987 and from 11 individuals in Chijipata in 1996. Analysis of the IgG4-ELISA resul ts revealed that there is highly significant linear relationship (P < 0.001 ) between the two methods of sampling. Most importantly, a reliable diagnos is was made with the blood-filter samples from Cutusuma, which had been sto red for 10 years at 40 degrees C. While some deterioration of the blood-fil ter samples from Cutusuma had occurred over the 10-year storage period, no deterioration occurred with the Chijipata samples, which were stored for on e year. Therefore, the method of collecting blood onto filter paper should prove useful for large-scale epidemiologic studies on human fascioliasis in the Bolivian Altiplano and in other regions where this disease is prevalen t.